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A B S T R A C T
Criteria used by the National Institute for Health and Care Excellence (NICE) to assess life-extending, end-of-life
(EoL) treatments imply that health gains from such treatments are valued more than other health gains. Despite
claims that the policy is supported by societal values, evidence from preference elicitation studies is mixed and
in-depth research has shown there are diﬀerent societal viewpoints. Few studies elicit preferences for policies
directly or combine diﬀerent approaches to understand preferences.
Survey questions were designed to investigate support for NICE EoL guidance at national and regional levels.
These ‘Decision Rule’ and ‘Treatment Choice’ questions were administered to an online sample of 1496 UK
respondents in May 2014. The same respondents answered questions designed to elicit their agreement with
three viewpoints (previously identiﬁed and described) in relation to provision of EoL treatments for terminally ill
patients. We report the ﬁndings of these choice questions and examine how they relate to each other and
respondents' viewpoints.
The Decision Rule questions described three policies: DA – a standard ‘value for money’ test, applied to all
health technologies; DB – giving special consideration to all treatments for terminal illnesses; and DC – giving
special consideration to speciﬁc categories of treatments for terminal illnesses e.g. life extension (as in NICE EoL
guidance) or those that improve quality-of-life (QoL). Three Treatment Choices were presented: TA – improving
QoL for patients with a non-terminal illness; TB – extending life for EoL patients; and TC – improving QoL at the
EoL.
DC received most support (45%) with most respondents giving special consideration to EoL only when
treatments improved QoL. The most commonly preferred treatment choices were TA (51%) and TC (43%).
Overall, this study challenges claims about public support for NICE's EoL guidance and the focus on life extension
at EoL and substantiates existing evidence of plurality in societal values.
1. Introduction
In 2009 the National Institute of Health and Care Excellence (NICE)
issued supplementary guidance for the appraisal of life-extending, end-
of-life (EoL) treatments (NICE, 2009). This guidance permits such
treatments to be recommended, even if they are not cost-eﬀective ac-
cording to usual standards, if certain criteria are met. These criteria are:
1) the treatment is for patients with short life expectancy normally less
than 24 months, 2) the treatment would oﬀer an extension to life of at
least 3 months, and 3) the treatment is licensed for a small patient
population (NICE, 2009). NICE, like other national Health Technology
Assessment (HTA) organisations, has adopted an approach to economic
evaluation based on cost utility analysis and applies a threshold cost per
quality-adjusted life year (QALY) of £30,000 (NICE, 2013). For tech-
nologies that meet the EoL criteria a threshold of £50,000 per QALY has
emerged over time (The Parliamentary Oﬃce of Science and
Technology, 2015) implying that life-extending QALYs for patients with
terminal illnesses are valued 1.7 times more than QALYs gained from all
other types of treatment.
By raising the threshold for, or giving additional weight to, life-
extending health gains at the EoL, the supplementary guidance suggests
that these health beneﬁts are of greater value (to society) than other
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types of health gains and that EoL might be considered a special case
(Rawlins et al., 2010). However, empirical evidence of societal support
for such a claim remains equivocal (Shah, 2017) and there is an op-
portunity cost to the EoL policy in terms of the health gains that would
have arisen if spending had been allocated in other ways (Collins and
Latimer, 2013). In this study, we examine societal preferences for
provision of life-extending treatments for people with a terminal illness
using two types of survey question, presenting respondents with choices
between ‘Decision Rules’ (designed to reﬂect policies of the type that
might be applied by national HTA organisations) and ‘Treatment
Choices’ (of the kind that might be made by a regional health board
with a ﬁxed budget).
1.1. Background
Empirical studies that elicit societal values around EoL have de-
ployed a variety of methods, including discrete choice methods (DCM)
(Rowen et al., 2016; Shah et al., 2015a; Skedgel et al., 2015), person
trade-oﬀ (PTO) (Pinto-Prades et al., 2014), budget allocation (Linley
and Hughes, 2013) and willingness to pay (WTP) (Pennington et al.,
2015; Pinto-Prades et al., 2014). The results of these studies have been
remarkably mixed. In a recent literature review, Shah (2017) identiﬁes
20 papers reporting empirical studies of societal values and EoL. Seven
papers ﬁnd a positive premium for EoL, nine negative and four report
mixed ﬁndings (see Shah (2017) for a detailed summary of these pa-
pers). Of these studies only three examined preferences for diﬀerent
types of health beneﬁt at the EoL; Pinto-Prades et al. (2014) and Shah
et al. (2014) found a preference for quality-of-life improvements and
Shah et al. (2015b) a preference for life extensions. The reason for such
mixed ﬁndings is not clear (Shah, 2017) but it is diﬃcult to explain
wholly on the basis of study design, sampling or elicitation methods.
One possible explanation is that such mixed ﬁndings reﬂect sub-
stantial moral disagreement. This hypothesis is supported by the ﬁnd-
ings of the ﬁrst phase of a two-phase study (funded by the Medical
Research Council (MRC) Methodology Panel: project ID number
G1002324) that used Q methodology to understand the nature of UK
societal perspectives around the relative value of life extensions for
people with a terminal illness (McHugh et al., 2015). Q methodology
combines qualitative and quantitative methods to study ‘subjectivity’ –
opinions, beliefs or values (Stephenson, 1953; Watts and Stenner,
2012). Data collection is via a card sort, and by-person factor analysis
enables shared views around a given topic to be identiﬁed and then
described; this methodology has previously been applied to the ﬁeld of
health (Baker et al., 2006; van Exel et al., 2015). Using this metho-
dology we identiﬁed three viewpoints: i) ‘A population perspective –
value for money, no special cases’, ii) ‘Life is precious – valuing life-
extension and patient choice’, iii) ‘Valuing wider beneﬁts and oppor-
tunity cost – the quality of life and death’. These viewpoints (described
in detail in the original paper) highlight the plurality of views that exist
in society around this topic and indicate that current NICE EoL policy
may ﬁnd little support. The viewpoints in this ﬁrst phase of work are
based around statements of opinion, principles and values relating to
the provision of life-extending treatments at the EoL. As such, they are
more abstract than most preference elicitation tasks, which tend to
describe speciﬁc (albeit hypothetical) choices and trade-oﬀs. A clear
strength of preference elicitation studies is that opportunity cost is
presented in terms of the choice foregone or through WTP (both imply
budget constraints). However, preference elicitation scenarios are often
attribute-based, can be brief or unrealistic and support for policy tends
to be inferred by aggregating responses to these tasks. In the context of
EoL, preference elicitation studies have resulted in such mixed ﬁndings
that simple aggregation and measures of central tendency likely conceal
heterogeneity. Combining preference elicitation with other approaches
might shed light on both the mixed ﬁndings in the existing literature
and whether respondents are consistent between their viewpoints and
stated preferences.
On the rare occasions that diﬀerent approaches have been combined
to examine societal values and EoL, inconsistent results have been
found. Rowen et al. (2014) presented attitudinal questions to re-
spondents, following a series of choice-based questions designed as a
Discrete Choice Experiment (DCE). Despite their DCE results indicating
some support for an EoL premium, responses to attitudinal questions
suggested limited support for life-extending treatments and patients at
the EoL. Shah et al. (2015b) explored whether respondents agreed with
the policy implications of their responses to stated preference tasks.
Respondents were ﬁrst asked to make choices between pairs of sce-
narios that were either abstract or ‘real-world’ resource allocation de-
cisions (the latter included qualitative descriptions of patients' quality-
of-life and information about the ages of patients instead of conceptual
diagrams depicting information about patients, medical conditions and
treatments as used in the former), and then were asked to state their
agreement (or not) with the implied policy implication of their choice.
Results suggested that some respondents struggled to align their views
with the need to make speciﬁc trade-oﬀs around prioritisation decisions
and that disagreement with the policy implications of their choice could
result from respondents diﬀering interpretation of policies. These re-
sults imply that responses to speciﬁc choices and trade-oﬀs may not
align with more general beliefs or views around life-extending EoL
treatments and that further exploration of this could help us understand
the mixed, empirical EoL ﬁndings.
In this paper we examine responses to speciﬁc choices as well as
agreement with more abstract viewpoints in relation to the provision of
life-extending treatments for people with a terminal illness (‘terminal
illness’ and ‘EoL’ are used interchangeably as the NICE supplementary
guidance uses the term ‘EoL’ (NICE, 2009) and their deﬁnition implies
‘terminal illness’). Respondents were asked to make choices framed
with respect to policies at a national level (‘Decision Rule’) and treat-
ment provision at a regional level (‘Treatment Choice’). One scenario in
each case is designed to mirror NICE EoL guidance. We elicit re-
spondents' support for the societal viewpoints identiﬁed in our earlier Q
methodological work (McHugh et al., 2015). We then examine how
choices between Decision Rules and Treatment Choices correspond to
each other and to the wider societal viewpoints.
2. Methods
2.1. Survey design
The survey was split into diﬀerent versions, one of which in-
corporated the Decision Rule and Treatment Choice questions. In
addition to these policy choice questions (described in more detail
below) respondents were asked to give Likert scale responses
(Viewpoint Questions) to indicate (dis)agreement with the three
viewpoints identiﬁed in McHugh et al. (2015). The questionnaire
concluded with socio-demographic questions. Appendix 1 shows the
script used in the introductory animation and Appendices 2-4 detail
the text of each question (accessed online at: http://www.gcu.ac.uk/
endoﬂife/onlinesurvey/).
2.2. Decision rule design
The Decision Rule (D) question (see Appendix 2) was designed to
represent the types of high-level rules applied to coverage decisions, at
a national level, by bodies like NICE and the Scottish Medicines Con-
sortium (SMC) in the UK. Speciﬁcally, respondents were asked to select
how a health system should assess drugs for terminally ill patients that
would not pass a standard ‘value for money’ (VFM) test (used as a lay
term for cost eﬀectiveness – see ‘Notes’ in Appendix 2 for deﬁnition).
Respondents were then presented with a choice between three mutually
exclusive policies: DA – a standard VFM test applied to all new health
technologies (‘DA – standard VFM test’); DB – permitting ‘special con-
sideration’ (i.e. provision of treatments even if the VFM is not passed)
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for all EoL treatments (‘DB – special consideration EoL’); and DC, per-
mitting special consideration to speciﬁc categories of new treatments
for terminal illnesses, such as those that extend life only or improve QoL
only (‘DC – EoL … it depends’). DC is most like the NICE EoL supple-
mentary guidance for those respondents selecting life extension as the
speciﬁc reason for special consideration.
2.3. Treatment choice design
The Treatment Choice question (see Appendix 3) was designed to
represent the types of decision that might be faced by Health Boards or
Clinical Commissioning Groups, confronted with a ﬁxed, additional
budget. Respondents ﬁrst selected their most-preferred treatment (A-C)
then their second-best treatment and following this one reason (from a
closed set of options) for their choice of most-preferred treatment. Next,
respondents were presented with two PTO questions (pairing their
most-preferred versus second-best treatments and their most-preferred
versus least-preferred treatments). TA – improving quality-of-life for
100 patients with a non-terminal illness (TA – Non-EoL-QoL) episodi-
cally for the rest of their life; TB - extending life by three months for 100
EoL patients (TB – EoL-LE), and TC - improving symptoms for 100
patients in the last year of their life (TC – EoL-QoL). The size of the
health gain from TA, TB and TC was implied rather than explicitly
stated within the treatment descriptions.
The PTO questions required respondents to choose between pro-
viding treatment to one of two patient groups in the context of a ﬁxed
budget (only one patient group could be treated); the number of pa-
tients in each group was initially set as equal (100). Respondents were
then asked to imagine that the cost of their preferred treatment
changed, meaning fewer patients could be treated in their preferred
group, while the other treatment could still treat 100 patients. The
number of patients in their preferred treatment group was altered be-
tween low and high numbers of treated patients, until a point of in-
diﬀerence was reached (Nord, 1995).
2.4. Viewpoint questions design
The Viewpoint Questions were designed to measure respondents'
agreement with one of three viewpoints, identiﬁed in earlier, in-depth
research using Q methodology. The ﬁrst viewpoint – ‘A population
perspective – value for money, no special cases’ – is a broadly utilitarian,
system-level perspective. Importance is given to maximizing the health
beneﬁts, from a ﬁxed health budget, to a population. Accordingly
treatments that yield greatest health improvements in relation to cost
should be prioritized and all patient groups should be considered
equally deserving of treatment. The second viewpoint – ‘Life is precious –
valuing life-extension and patient choice’ – is an individual patient per-
spective and is based on rights-based arguments and views about en-
titlement. Human life is considered precious and treatments should not
be denied because of cost. Consequently no treatments are viewed as
being a special case, rather the key criteria is that if a patient wants a
treatment, including life-extending treatments at the EoL, they should
have it because everyone contributes to the funding of the NHS. The
third viewpoint – ‘Valuing wider beneﬁts and opportunity cost - the quality
of life and death’ – is similar to the ﬁrst as it recognizes the importance
of achieving value for money from the health budget. However, this
viewpoint also appreciates that there may be value for patients and
their families from receiving treatment that goes beyond the measur-
able health beneﬁts typically used in standard cost-beneﬁt calculations.
For more detail on these viewpoints see McHugh et al. (2015).
Salient and distinguishing statements from the original Q study
were selected to characterise each of the viewpoints (see Appendix 4)
following methods described in Baker et al. (2010a, 2014) and Mason
et al. (2016). Six statements were identiﬁed to distinguish each of the
three viewpoints, resulting in a set of 18 statements selected from the
original 49 statements (McHugh et al., 2015). Crucially, these
statements are used as ‘ﬂags’ to signal allegiance with the whole
viewpoint, they do not ‘sum up’ the viewpoint in its entirety.
Each of the 18 statements was presented to survey respondents, in
random order, accompanied by a 7-point Likert scale labelled from
“completely disagree” to “completely agree”. On completion, three
scores were calculated for each respondent, indicating their level of
agreement with each of the three viewpoints. Respondents were as-
signed to the viewpoint consistent with their highest score and to the
category ‘mixed’ if their highest scores were equal on more than one
viewpoint.
2.5. Data collection
The online survey was programmed and administered by YouGov
(www.yougov.co.uk) and can be viewed and completed via the project
website: http://www.gcu.ac.uk/endoﬂife/onlinesurvey/.
Prior to programming, survey questions were piloted in six focus
groups with members of the public (n=54), recruited via a market
research company to ensure variation across socio-demographic char-
acteristics (age, gender and income). In addition, prior to and after
programming survey questions were piloted with a convenience sample
of university colleagues to test the design, wording and comprehension
of questions. Qualitative probing during the pilot led to a better un-
derstanding of how respondents interpreted the questions and question
wording was amended accordingly. For example, in TA (Non-EoL-QoL)
respondents asked if the duration of quality-of-life improvement was for
the rest of the patients' life so the words “for the rest of their life” were
added.
Respondents to the main survey were quota sampled from YouGov's
UK online survey panel to represent the UK population on the basis of
age, gender, socio-economic group (SEG) and ethnicity.
The survey was structured as follows: ﬁrst, a short animated video
(created speciﬁcally for this project) introduced and set the context for
the survey (see http://www.gcu.ac.uk/endoﬂife/onlinesurvey/
introductoryanimation/). The video describes, in simple terms, the is-
sues of scarcity and opportunity cost within the NHS and the need to
make decisions about the provision of treatments and services. It ex-
plains that many diﬀerent things could be considered when making
decisions about how best to allocate resources, such as severity of ill-
ness or quality-of-life, and that in this research the focus was on
treatments that help terminally ill patients live longer (see Appendix 1).
Following the introduction, the 18 Viewpoint Questions were pre-
sented followed by the Decision Rule and then Treatment Choice
questions. The survey ﬁnished with a number of socio-demographic
questions.
2.6. Data analysis
As online surveys are susceptible to ‘clicking through’ and to re-
spondents being distracted, those who completed the survey very
quickly (less than 7min and 30 s) or very slowly (longer than 2 h) were
excluded from the analysis. Respondents who completed the survey in
less than 7min and 30 s, were considered to have reached completion
too quickly to have fully read and understood the tasks. Similarly, those
respondents who took more than 2 h to reach completion, might not
have fully engaged with the survey and the time taken to complete may
have inhibited their ability to recall the premise of the survey outlined
in the introductory video. It is possible that, by imposing these rules,
valid responses were excluded. However, these conservative cut-oﬀ
times were based on the judgment of the research team informed by
timed testing of the survey. Sensitivity analysis was conducted to ex-
amine the impact of imposing these exclusions on ﬁndings.
Summary statistics detailing frequencies for both the Decision Rule
and Treatment Choice questions were calculated. Hypotheses about
which choice of treatment would logically follow from respondents'
decision rule are shown in Table 1.
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If respondents' choice of treatment reﬂects their decision rule those
selecting Decision Rule DA would be more likely to choose Treatment
Choice TA as this choice reﬂects a preference for maximizing health
gains from a ﬁxed budget. Respondents selecting DB favour all treat-
ments for terminal illnesses so are likely to choose TB or TC. Similarly
these two treatments – TB and TC – are also likely to be selected by
those who prefer DC.
PTO ratios were calculated, reﬂecting respondents' strength of pre-
ference for treatment choices. While there is no single, correct approach
for aggregating PTO ratios, there is consensus that one method – cal-
culating the ‘mean of ratios’ – should be avoided. Following Baker et al.
(2010b), Chilton et al. (2002), and Pinto-Prades et al. (2014), we cal-
culated the ‘ratio of means’ and the ‘median of ratios’ (see Appendix 5
for details and illustrative calculations).
The relationship between respondents' decision rule and treatment
choices and their viewpoints was also hypothesised (see Table 2). Si-
milar predictions (as detailed in Table 1) were made about which
choices of decision rule and treatment choices would logically follow
from respondents' viewpoints.
If choices reﬂect viewpoints then respondents associated with
Viewpoint 1 (a broadly utilitarian account) would be more likely to
choose Decision Rule DA and Treatment Choice TA because these
choices would maximize health beneﬁts. Respondents associated with
Viewpoint 2 believe that patient choice is paramount and life is pre-
cious, and that cost should not drive decisions about treatment provi-
sion so no clear decision rule or treatment choice preference follow. We
might predict, however, that those holding Viewpoint 2 would object to
a strict value for money approach that overrules patient choice on the
grounds that they reject consideration of cost. Respondents who agree
most with Viewpoint 3 are likely to prefer DC, TA and TC as quality-of-
life is reﬂected in these choices; DA could also be chosen because of
value for money concerns but may be considered too narrow a decision
rule for this account.
2.7. Research ethics
Ethical approval for this study was obtained from the School of
Health and Life Sciences Ethics Committee, Glasgow Caledonian
University (reference B11/04).
3. Results
3.1. Sample size, exclusion criteria and characteristics
Data were collected in May 2014. The full sample across all survey
versions totaled 5496 respondents and was quota sampled from
YouGov's online panel to be nationally representative with respect to
age, gender, SEG and ethnicity. 1657 respondents were randomly al-
located to the Policy Choice Version; after exclusion of respondents
based on completion times the Policy Choice Version totaled 1496
(Table 3 details respondents socio-demographic characteristics in total
and according to their policy choices). Sensitivity analysis showed that
the use of exclusion rules made no diﬀerence to the percentages se-
lecting options within the Decision Rule and Treatment Choice ques-
tions.
3.2. Relationship between policy choices and respondent characteristics
The relationship between respondents' socio-demographic char-
acteristics and their policy choices (Decision Rule and Treatment
Choice) is shown in Table 3. Respondents' gender, age, ethnicity, SEG,
education and income were statistically signiﬁcantly related to their
choice of Decision Rule. Males were more likely to choose DA and fe-
males to choose DC; those selecting DB were younger than those se-
lecting DA or DC and more-likely to be non-white; those with high
educational qualiﬁcations, socio-economic status and income more
often selected DA whereas respondents with low qualiﬁcations and
income more often chose DB. Responses to Treatment Choice questions
appeared to be related to gender, age, and education but in general,
there were fewer statistically signiﬁcant relationships. Males were more
likely to choose TB and females to choose TC; those selecting TB were
younger than those selecting TA or TC; and those with low educational
qualiﬁcations chose TB whereas those with high qualiﬁcations selected
TA.
3.3. Decision rule results
Table 4 shows the results from the Decision Rule question. DB was
the least popular policy when respondents were asked ‘which one of the
following policies do you agree with most?’, and overall there was a
preference for giving special consideration to treatments for terminal
illnesses in some (albeit not all) situations. Of the 669 respondents who
selected DC, a large majority (72%) stated that treatments that improve
quality-of-life for terminally ill patients should be given special con-
sideration; only 10% stated special consideration should be given to
treatments that extend life. When asked about the role cost should play
in the provision of DB or DC, 56% of the 293 respondents who preferred
DB thought this policy should be implemented regardless of cost,
whereas 63% of the 669 respondents who preferred DC agreed there
should be some limit to the amount the NHS pays to implement this
policy.
Table 1
Hypotheses: Decision rule and treatment choice.
Decision Rule Treatment Choice
TA (Non-EOL-QoL) TB (EoL-LE) TC (EoL-QoL)
DA (standard VFM test) Yes No No
DB (special consideration EoL) No either potentially consistent
DC (EoL … it depends) No either potentially consistent
Table 2
Hypotheses: Viewpoints and policy choices.
Views Decision Rule Treatment Choice
DA (standard VFM
test)
DB (special consideration
EoL)
DC (EoL … it
depends)
TA (Non-EoL-
QoL)
TB (EoL-
LE)
TC (EoL-
QoL)
Viewpoint 1 (A population perspective: value for money,
no special cases)
Yes No Yes No
Viewpoint 2 (Life is precious: valuing life-extension and
patient choice)
No Unclear Unclear
Viewpoint 3 (Valuing wider beneﬁts and opportunity
cost: the quality of life and death)
Unclear No Yes Yes No Yes
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3.4. Treatment choice results
3.4.1. Ranking results and reason for choice
Table 5 presents the ranking results from the Treatment Choice
question. Just over half of respondents (51%) chose to provide TA from
the additional available budget (quality-of-life-improving treatment for
non-terminal illness (Non-EoL-QoL)). A substantial number of re-
spondents (43%) preferred TC (quality-of-life-improving treatment for a
Table 3
Respondent characteristics: Total sample, Decision Rule and Treatment Choice.
Variables Total Sample Decision Rule Treatment Choice
DA (standard
VFM test)
DB (special
consideration EoL)
DC (EoL … it
depends)
Pˆ TA (Non-EoL-
QoL)
TB (EoL-LE) TC (EoL-QoL) Pˆ
N % N % N % N % N % N % N %
Gender 0.1a* <0.01a***
Male 739 49.4 282 52.8 145 49.5 312 46.6 386 50.6 54 63.5 299 46.1
Female 757 50.6 252 47.2 148 50.5 357 53.4 377 49.4 31 36.5 349 53.9
Age 0.03 a** <0.01 a***
18-29 247 16.5 91 17 61 20.8 95 14.2 133 17.4 18 21.2 96 14.8
30-49 511 34.2 165 30.9 105 35.8 241 36.0 256 33.6 42 49.4 213 32.9
50-64 380 25.4 133 24.9 74 25.3 173 25.9 184 24.1 20 23.5 176 27.2
65-74 197 13.2 78 14.6 29 9.9 90 13.5 97 12.7 4 4.7 96 14.8
75+ 161 10.8 67 12.5 24 8.2 70 10.5 93 12.2 1 1.2 67 10.3
Ethnicity 0.02 a** 0.4 a
White 1364 91.2 497 93.1 254 86.7 613 91.6 701 91.9 74 87.1 589 90.9
Non-white 104 7 30 5.6 31 10.6 43 6.4 50 6.6 9 10.6 45 6.9
Prefer not to say 28 1.9 7 1.3 8 2.7 13 1.9 12 1.6 2 2.4 14 2.2
Country 0.9b 0.3b
England 1227 82 439 82.2 239 81.6 549 82.1 627 82.2 73 85.9 527 81.3
Wales 80 5.3 28 5.2 16 5.5 36 5.4 32 4.2 5 5.9 43 6.6
Scotland 165 11 61 11.4 31 10.6 73 10.9 91 11.9 7 8.2 67 10.3
Northern Ireland 24 1.6 6 1.1 7 2.4 11 1.6 13 1.7 0 0 11 1.7
SEGc 0.02 a** 0.8 a
AB (SEG) 461 31 178 33.5 75 25.7 208 31.4 234 30.9 22 25.9 205 31.8
C1 (SEG) 451 30.3 167 31.4 93 31.8 191 28.8 230 30.4 29 34.1 192 29.8
C2 (SEG) 234 15.7 86 16.2 49 16.8 99 14.9 125 16.5 14 16.5 95 14.7
DE (SEG) 341 22.9 101 19 75 25.7 165 24.9 168 22.2 20 23.5 153 23.7
Education
Qualiﬁcations
<0.01 a*** 0.06 a*
Low qualiﬁcations 350 23.4 108 20.2 86 29.4 156 23.3 166 21.8 27 31.8 157 24.2
Mid qualiﬁcations 398 26.6 132 24.7 77 26.3 189 28.3 198 26.0 20 23.5 180 27.8
High
qualiﬁcations
712 47.6 283 53.0 122 41.6 307 45.9 383 50.2 35 41.2 294 45.4
Don't know 9 0.6 1 0.2 3 1.0 5 0.7 5 0.7 1 1.2 3 0.5
Prefer not to say 27 1.8 10 1.9 5 1.7 12 1.8 11 1.4 2 2.4 14 2.2
Income <0.01 a*** 0.8 a
Low income 349 23.3 106 19.9 82 28.0 161 24.1 180 23.6 19 22.4 150 23.1
Middle income 444 29.7 163 30.5 80 27.3 201 30.0 237 31.1 25 29.4 182 28.1
High income 341 22.8 148 27.7 57 19.5 136 20.3 178 23.3 15 17.6 148 22.8
Don't know 80 5.3 26 4.9 18 6.1 36 5.4 36 4.7 4 4.7 40 6.2
Prefer not to
answer
282 18.9 91 17.0 56 19.1 135 20.2 132 17.3 22 25.9 128 19.8
Total 1496 534 35.7 293 19.6 669 44.7 763 51 85 5.7 648 43.3
ˆ ‘Don't know’ & ‘Prefer not to say’ excluded from p-value calculation.
***1% signiﬁcance level; **5% signiﬁcance level; *10% signiﬁcance level.
a Kruskal-Wallis tests.
b Chi-Square tests.
c n=1487 because of missing data.
Table 4
Decision rule results and reasons (n=1496).
DA (standard VFM test) DB (special consideration EoL) DC (EoL … it depends)
Total selecting this policy 534 (36%) 293 (19%) 669 (45%)
Valuing types of health gain – – Improve QoL 485 (72%)
– – Extend Life 64 (10%)
– – Depending on. .a 120 (18%)
Regardless of cost – 165 (56%) 246 (37%)
Limit to cost – 128 (44%) 423 (63%)
a Special consideration depends on something else, either: patients having known about their terminal illness for only a short period of time; patients not having had their fair innings
in terms of length of life; life extension only being valued if quality-of-life is not poor or another (entered) reason.
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terminal illness (EoL-QoL)); only 6% preferred TB (life-extending
treatment for a terminal illness (EoL-LE)). Examination of second-
choice treatments reveals that TB (EoL-LE) remains the least-preferred
treatment, while more respondents prefer TC (EoL-QoL) (48%) to TA
(Non-EoL-QoL) (35%). The majority of respondents placed TB in third
place (78%), whereas TC was ranked third by the least number of re-
spondents (9%).
Respondents also chose one reason for selecting their preferred
choice of treatment. Respondents who most-preferred TA did so be-
cause it would provide a larger health beneﬁt gain (34%), it would
improve quality-of-life (26%) and the illness aﬀects patients for the rest
of their life (22%). Quality-of-life improvement was also the primary
reason behind the preferred selection of TC (77%). Those preferring TB
did so mainly because it would extend life (50%).
3.5. PTO results
PTO questions paired respondents' most-preferred versus second-
best treatment (1 vs. 2) and most-preferred versus least-preferred
treatment (1 vs. 3); the totals in Table 5 detail the aggregated order in
which each of the three treatments was ranked. Data from both PTO
questions – 1 vs. 2 and 1 vs. 3 – were combined in order to aggregate
responses for each pair of treatments – TA and TB, TA and TC and TB
and TC. Counts, ratios and ‘extreme preferences’ (taken as the number
of respondents who consider that fewer than 10 patients receiving one
treatment is equivalent to 100 patients receiving the other) are shown
in Table 6.
While the initial ranking of treatments (see Table 5) indicates the
ordering of treatments, examination of PTO data provides insight into
the magnitude of preferences between pairs of treatments. For the pair
TA versus TC both (the ‘ratio of means’ and the ‘median of ratios’) are
close to one, suggesting that respondents value the two treatments si-
milarly (0.93 and 0.98). Ratios indicate greater strength of preference
for TA or TC when compared to TB.
In an attempt to ‘unpack’ the data a little, Table 6 also shows 'ex-
treme preferences’. While a substantial proportion of respondents' make
these extreme choices, the most pronounced diﬀerences are seen in the
pairings when either TA or TC is set against TB (59% v 44% and 60% v
42%). In pair TA versus TC, despite ratios suggesting a slight preference
for TA over TC there is a greater proportion of extreme preferences
among respondents who prefer TC than those who prefer TA (51% vs.
44%). This is balanced against the fact that a greater number of re-
spondents prefer TA.
The results of Treatment Choice, like the Decision Rule questions,
indicate a preference for quality-of-life improving treatments for both
non-terminal and terminal illnesses compared to life-extending treat-
ments for the terminally ill.
3.6. Relationship between decision rule and treatment choices
Table 7 cross-tabulates Decision Rule and Treatment Choices. As
hypothesised (see Table 1), those who selected DA more often chose TA
(70%) and to a lesser extent TC (27%); TB was rarely chosen. Those
who selected DB most commonly chose TC (57%), as predicted, but,
unexpectedly, more DB respondents selected TA (33%) than chose TB
(10%). This pattern of response was the same for DC respondents: most
chose TC (50%) as expected but a large number selected TA (44%) over
TB (6%). This latter result is not wholly surprising, though, given that
the majority of respondents who chose DC stated special consideration
depends on improvements in quality-of-life (see Table 4).
Table 6
Treatment Choice PTO results.
X vs. Y TA (Non-EoL-QoL) vs. TB (EoL-LE) TA (Non-EoL-QoL) vs. TC (EoL-QoL) TC (EoL-QoL) vs. TB (EoL-LE)
Prefer X (%) 763 (90%) 763 (54%) 648 (88%)
Extreme preference:< 10X=100Y 450 (59%) 335 (44%) 388 (60%)
Prefer Y (%) 85 (10%) 648 (46%) 85 (12%)
Extreme preference:< 10Y=100X 37 (44%) 330 (51%) 35 (42%)
Mean prefer X 33 65 35
Mean prefer Y 95 70 94
Ratio of means X:Y (Y= 1) 0.34 0.93 0.37
Median of ratios (Y=1) 0.08 0.98 0.08
Total 848 1411 732a
a PTO 1 v 3 data is missing from one individual.
Table 7
Relationship: Decision rule and treatment choice.
Treatment Choice Total
TA (Non-
EoL-QoL)
TB (EoL-
LE)
TC (EoL-
QoL)
Decision Rule DA (standard VFM
test)
70.0% 2.8% 27.2% 534
DB (special
consideration EoL)
33.1% 10.2% 56.7% 293
DC (EoL … it
depends)
43.6% 6.0% 50.4% 669
Total) 1496
Table 5
Treatment choice ranking results.
Total (%) Second choice (%)
TA (Non-EoL-QoL) TB (EoL-LE) TC (EoL-QoL)
First choice (%) TA (Non-EoL-QoL) 763 (51.0) – 93 (6.2) 670 (44.8)
TB (EoL-LE) 85 (5.6) 38 (2.5) – 47 (3.1)
TC (EoL-QoL) 648 (43.4) 489 (32.7) 159 (10.6) –
Total (%) 1496 (100) 527 (35.2) 252 (16.8) 717 (47.9)
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3.7. Relationship between viewpoints and policies
The results in Table 8 show that 37% of respondents were matched
with Viewpoint 1 (‘A population perspective – value for money, no
special cases’). Just under half of the respondents (49%) were matched
with Viewpoint 2 (‘Life is precious – valuing life-extension and patient
choice’) and 9% matched with Viewpoint 3 (‘Valuing wider beneﬁts and
opportunity cost – the quality of life and death’).
Table 8 shows a statistically signiﬁcant pattern between re-
spondents' viewpoints and their policy choices; this pattern broadly
reﬂects the hypotheses outlined in Table 2. Respondents associated
with Viewpoint 1 were more likely to choose Decision Rule DA (56%)
than DC (36%) or DB (8%) and, also as predicted, favour Treatment
Choice TA (69%). Predictions were more diﬃcult for Viewpoint 2 for
reasons already mentioned. However, as expected, DA, which proposes
a strict value for money approach, was the least preferred decision rule
for those associated with Viewpoint 2 (17%). Unexpectedly respondents
who were associated with Viewpoint 3 were more likely to select DA
(53%) then DC (36%); few chose DB (11%). As predicted Viewpoint 3
respondents were more likely to choose a quality-of-life improving
treatment – TA (62.4%) or TC (36%) – than one that extends life TB
(2%). Respondents associated with Viewpoint 1 and Viewpoint 3 had a
similar pattern of response to Decision Rule and Treatment Choice
questions which could be a result of the relatively high correlation
(0.68) between these viewpoints (McHugh et al., 2015). Although this
may also relate to the relatively small number of respondents identiﬁed
as Viewpoint 3 (n= 141).
4. Discussion
This paper reports the ﬁndings of a national survey of the UK gen-
eral population investigating societal preferences for provision of life-
extending treatments for people with a terminal illness framed with
respect to policies at a national level (Decision Rule) and treatment
provision at a regional level (Treatment Choice). Results challenge
NICE's current EoL guidance as there is very little support for prior-
itising life-extending treatments for terminal illnesses over and above
other treatments. Substantial support is found for quality-of-life im-
proving treatments at the EoL and for policies which account for the
costs of new treatments.
While Decision Rule ﬁndings showed the majority of respondents
supported giving special consideration to assessing treatments for
terminal illnesses (taking DC and DB together), this ﬁnding was quali-
ﬁed. More support was given to DC, which suggests that special con-
sideration should be given to terminal illnesses in health care priority
setting only in certain situations; with a focus on treatments that im-
prove quality-of-life. Faced with Treatment Choices, respondents
prioritized quality-of-life over life extension with preference for TA and
TC over TB which aligned with the strength of preference results for
these pairings; PTO results also indicated a substantial proportion of
respondents made limited trade-oﬀs (extreme preferences). Examining
agreement with the three societal viewpoints indicated that our sample
disagreed regarding the role cost should play in decision-making. While
49% of respondents were assigned to Viewpoint 2, an account that
suggests that costs should not play a role in decision making, 46% of
respondents (Viewpoint 1 and 3) recognized the importance of
achieving value for money.
Exploration of the relationship between diﬀerent Decision Rules and
Treatment Choices found encouraging results as we observe broad
consistency between respondents' preferences elicited from those
choices. An unexpected observation was the proportion of respondents
who selected Decision Rules that gave EoL treatments special con-
sideration and preferred the Non-EoL-QoL health maximizing treatment
(TA) (33% of those selecting DB and 44% of those selecting DC). This
could be explained by the health gains of TA arising over patients'
lifetimes and so respondents might reasonably have interpreted these as
far exceeding the health gains likely to arise from 100 patients receiving
either TB or TC. While this could indicate a disconnect between dif-
ferent types of preference, it could also be the case that preference for
EoL is outweighed if the health gain from the alternative treatment is
substantial. Unfortunately the online nature of our survey meant these
issues could not be explored qualitatively.
Examining the pattern of response between respondents' viewpoints
and their choices indicates that while in the majority of cases there is a
pattern in line with expectations; it is not always the case. However, a
priori hypotheses are not straightforward because viewpoints are wider
and take in other issues, and choices were designed to examine support
for NICE EoL policy rather than to mirror viewpoints exactly. Despite
this limitation, interesting ﬁndings emerged. Results suggest that when
respondents make choices they are more attuned to the limits of the
NHS budget than when responding in more general terms when op-
portunity cost is not always explicit (Viewpoint Questions). More re-
search is needed to examine the nature of consistency between princi-
ples, policies and choices, if policy is to be designed in areas of societal
disagreement. As well as future work qualitatively exploring incon-
sistencies, the separation of preferences into diﬀerent ‘levels’ – princi-
ples, policies and choices – of speciﬁcity and abstraction would enable
examination of why and how respondents (dis)agree and whether there
is potential for agreement in more-speciﬁc cases in the face of dis-
agreement at the level of theory or principle (Sunstein, 1995).
Table 8
Respondent viewpoints and policy choices.
Variables Total
Sample
Decision Rule Treatment Choice
DA (standard
VFM test)
DB (special
consideration EoL)
DC (EoL … it
depends)
Pˆ TA (Non-
EoL-QoL)
TB (EoL-
LE)
TC (EoL-
QoL)
Pˆ
N N (%) N (%) N (%) N (%) N (%) N (%)
Viewpoint < 0.01*** < 0.01***
V1: A population perspective: value
for money, no special cases
558 311 (55.7) 47 (8.4) 200 (35.9) 385 (69.0) 13 (2.3) 160
(28.7)
V2: Life is precious: valuing life-
extension and patient choice
736 128 (17.4) 218 (29.6) 390 (53.0) 258 (35.0) 66 (9) 412
(56.0)
V3: Valuing wider beneﬁts and
opportunity cost: the quality of
life and death
141 74 (52.5) 16 (11.3) 51 (36.2) 88 (62.4) 3 (2.1) 50 (35.5)
Mixed 61 21 (34.4) 12 (19.7) 28 (45.9) 32 (52.5) 3 (4.9) 26 (42.6)
Total 1496 534 (35.7) 293 (19.6) 669 (44.7) 763 (51.0) 85 (5.7) 648
(43.3)
ˆp-values calculated using Chi-Square tests (the ‘mixed’ category was excluded from the calculation).
***1% signiﬁcance level.
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The empirical literature eliciting societal values with respect to
provision of EoL treatments has, to date, produced very mixed results
with a similar number of papers reporting an EoL premium or no evi-
dence of such a premium (Shah, 2017). Our survey methods, grounded
in a previous, in-depth study of the nature of perspectives (McHugh
et al., 2015), suggest a substantial proportion of the population
(roughly a third of our sample) has broadly utilitarian motivations,
preferring policies promoting cost eﬀectiveness and maximizing health
gains. In contrast to current NICE policy, which favours life-extending
treatments at the EoL, our results also suggest that policies and treat-
ments that prioritise quality-of-life are more important to the general
population than those that prioritise length of life. On the basis of these
ﬁndings, and the ﬁndings of Pinto-Prades et al. (2014) and Shah et al.
(2014), life extension appears to be less valued by the public than
quality-of-life at the EoL. This is an important observation given that
media reports and other policy initiatives (e.g. Cancer Drugs Fund)
might suggest that society values life-extending treatments above other
treatments and services competing for funds. If additional societal
beneﬁts are not generated from prioritising funding for life-extending
treatments at the EoL, then cost-eﬀective treatments for non-EoL pa-
tients may be displaced by policies that prioritise less eﬃcient treat-
ments.
4.1. Limitations
There are a number of limitations to the study design and details of
the survey that should be acknowledged. Firstly, respondents were
quota-sampled to represent the general population with respect to
standard socio-demographic variables, but they were members of
YouGov's online survey panel, which introduces self-selection bias.
Furthermore, a trade-oﬀ of undertaking large scale survey work is that
we were unable to collect qualitative data alongside the main survey.
As such, we could not explore qualitatively: why, in some cases, the
relationships between Decision Rule and Treatment Choice responses,
or between policy choices and viewpoints, were not as expected;
whether and to what extent respondents viewed TA (Non-EoL-QoL) as
the health maximizing treatment; nor respondents' rationales for their
treatment choices to move beyond the circularity of re-stating details of
the scenarios chosen.
Secondly, question ordering may have aﬀected responses. We took
the view that there was need for a consistent ordering as Viewpoint
Questions introduce diﬀerent issues related to the topic, and Treatment
Choice selection was considered to ﬂow more naturally from the choice
of a high-level Decision Rule, but we cannot rule out the ordering ef-
fects that may have followed from this design.
Thirdly, the Decision Rule question could have introduced a ‘status
quo’ framing eﬀect by stating that the NHS currently applies a ‘value for
money’ test before agreeing to provide new medicines. Thus re-
spondents might have seen this as a choice between the status quo (DA)
and something new – DB or DC – although the status quo is in reality
closer to DC (along with a preference for life extension). Respondents
could have been unwilling to choose a policy that contradicts the cur-
rent agenda. However, our results show that DC (with a quality-of-life
preference) was the most popular choice.
Fourthly, as shown in Table 2, no viewpoints clearly correspond to a
preference for DB or TB because none of the three viewpoints from our
original study would clearly predict those decision rule or treatment
choices (McHugh et al., 2015). DB was included to examine if re-
spondents valued all new treatments for terminal illnesses and TB re-
presents NICE's current EoL policy.
Fifthly, in the introduction to the Decision Rule question the terms
‘drugs’ and ‘treatments’ could be construed as being interchangeable;
this was not our intention and a clearer diﬀerentiation should have
been made between the two as per NICE technology appraisal guidance
(NICE, 2017). Whilst this could have led to diﬀerent interpretations
amongst respondents, we were given no indication of this during the
piloting phase and the decision rule and treatment choice scenarios all
refer to ‘treatments’. The focus on treatments is similar to the approach
used in the EoL preference elicitation literature summarized in the
‘Background’ section. However, whether ‘treatment’ refers to drugs or
something else is generally unstated in these papers; exploring pre-
ferences for diﬀerent types of treatment at the EoL could be an inter-
esting source of future research.
Lastly, respondents were assigned to a viewpoint based on their
highest aggregate score on associated statements. While this gives an
indication of what viewpoint respondents are most like it does not ac-
count for respondents being closely associated with multiple view-
points. Given that quality-of-life receives substantial support from the
policy choice questions, this could help to explain the unexpectedly
small proportion of respondents (9%) assigned to Viewpoint 3.
5. Conclusion
This study challenges NICE's current EoL guidance and contributes,
through use of innovative methods, to the growing body of empirical
evidence around this topic. Elicited preferences indicate that for policy
to better reﬂect societal values consideration needs to be given to
quality-of-life improving treatments at the EoL and to the cost of new
treatments. Our ﬁndings also caution against simplistic approaches to
summarizing societal values using measures of central tendency. The
methods used reveal plural societal views and that diﬀerent relation-
ships can exist between societal viewpoints and preferences expressed
at diﬀerent levels of speciﬁcation. Future research should combine
qualitative and quantitative methods to better understand the nature
and distribution of societal values across diﬀerent levels of speciﬁcity
and abstraction. There would appear to be great potential in developing
empirical studies of societal values that combine health economic and
ethics based approaches, examining the relationship between princi-
ples/arguments and choices/preferences.
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